There are separate treatment pathways for individuals with a class A and class B CPS and for people with a class C CPS. Also, the authors offer an algorithmic approach to these agents inside the transplant inhabitants, focusing on initial line usage of glucagon-like peptide one (GLP-one) agonists because https://garrettjrwcf.ampedpages.com/not-known-facts-about-glp-1-patches-63697843